Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2026 22:47 ET | Source: InnoCare Pharma

ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released

InnoCare's novel BCL2i mesutoclax in MDS and AML was released at 2026 ASCO as an oral presentation, demonstrating outstanding efficacy and safety.
May 22, 2026 08:00 ET | Source: InnoCare Pharma

2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released

The data show that mesutoclax demonstrates outstanding efficacy and safety in treating various hematologic malignancies.
February 25, 2026 22:56 ET | Source: InnoCare Pharma

InnoCare Announces Key Developments of Critical Clinical Studies

InnoCare announced key clinical development progress, including the completion of patient enrollment of multiple Phase III registrational trials.
August 21, 2025 09:24 ET | Source: InnoCare Pharma

InnoCare Announces First Patient Dosed in the Registrational Trial of BCL2 Inhibitor Mesutoclax for Treatment of BTKi-treated MCL Patients in China

The first patient has been dosed in the registrational trial of InnoCare's BCL2 inhibitor mesutoclax for patients with BTK inhibitor treated MCL in China.